Direkt zum Inhalt
Merck

P0123

Sigma-Aldrich

Anti-Paraoxonase 1 (PON1) in Kaninchen hergestellte Antikörper

~1 mg/mL, affinity isolated antibody, buffered aqueous solution

Synonym(e):

Anti-Arylesterase, Anti-Coronary Artey Disease, Susceptibility to, Anti-Coronary Spasms, Susceptibility to, Anti-Esterase A (ESA), Anti-Organophosphate Poisoning, Sensitivity to, Anti-PON1, Anti-Parathion Poisoning, Sensitivity to

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

MDL-Nummer:
UNSPSC-Code:
12352203
NACRES:
NA.41

Biologische Quelle

rabbit

Qualitätsniveau

Konjugat

unconjugated

Antikörperform

affinity isolated antibody

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Form

buffered aqueous solution

Mol-Gew.

antigen ~40 kDa

Speziesreaktivität

mouse (predicted), rat (predicted), human

Konzentration

~1 mg/mL

Methode(n)

indirect immunofluorescence: 5-10 μg/mL using human HT-29 cells
western blot: 0.5-1 μg/mL using whole extract of human colorectal adenocarcinoma HT-29 cells

UniProt-Hinterlegungsnummer

Versandbedingung

dry ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... PON1(5444)
mouse ... Pon1(18979)
rat ... Pon1(84024)

Allgemeine Beschreibung

Paraoxonase-1 (PON1) is a member of serum paraoxonases family, consisting of PON1, PON2, and PON3. Human PONs map to the long arm of chromosome 7. PON1 is polymorphic in human populations, and different individuals express widely different levels of this enzyme. PON1 and PON3 are expressed in the liver and secreted into the blood where they are associated with the high-density lipoprotein (HDL) particle.

Immunogen

synthetic peptide corresponding to amino acids 298-309 of human PON1, conjugated to KLH via an N-terminal cysteine residue. The corresponding sequence differs by one amino acid in mouse and two amino acids in rat. The peptide sequence differs by one amino acid in human PON2 and two amino acids in human PON3.

Anwendung

Anti-Paraoxonase 1 (PON1) antibody produced in rabbit has been used in immunoblotting, and immunofluorescence .

Biochem./physiol. Wirkung

Paraoxonase-1 (PON1) protects lipids from oxidation in lipoproteins, macrophages, and erythrocytes. PON1 may confer protection against coronary artery disease by destroying proinflammatory oxidized lipids present in oxidized low-density lipoproteins (LDLs). PON1 plays a key role in the detoxification of organophosphate insecticides such as parathion, chlorpyrifos and diazinon and nerve gases such as soman and sarin.

Physikalische Form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Produkt-Auswahlhilfe.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Tomas Vaisar et al.
Diabetes care, 43(1), 178-186 (2019-10-11)
A subset of people with long-standing type 1 diabetes (T1D) appears to be protected from microvascular and macrovascular complications. Previous studies have focused on improved abilities to respond to glucose and its downstream effects as protective mechanisms. It is unclear
Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity
Koitka M, et al.
Journal of Pharmaceutical and Biomedical Analysis, 51, 664-678 (2010)
Targeted proteomics identifies paraoxonase/arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone
Ronsein GE, et al.
Molecular and Cellular Proteomics, 15(3), 1083-1093 (2016)
Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance
Shunmoogam N, et al.
Vascular Health, 14(3), 137-137 (2018)
Graziella E Ronsein et al.
Molecular & cellular proteomics : MCP, 15(3), 1083-1093 (2015-12-17)
Low levels of high-density lipoprotein cholesterol (HDL-C) and high triglyceride levels contribute to the excess rate of cardiovascular events seen in subjects with type 2 diabetes. Fenofibrate treatment partially reverses dyslipidemia in these subjects. However, a paradoxical marked reduction in

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.